Pharming Group N.V. today announced presentations at the 2026 Annual Meeting of the Clinical Immunology Society (CIS), taking place May 6-9 in New Orleans, LA.

Pharming Group N.V. presents its preliminary unaudited financial report for the three months ended March 31, 2026.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the first quarter 2026 and provide a business update on Thursday, May 7, 2026.

Pharming Group N.V. today announced that the Company’s 2026 Annual General Meeting of Shareholders (the “AGM”) will be held on Thursday May 28, 2026, at 14:00 CET.

Pharming Group N.V. today announced that its management will participate in the following investor conferences in the month of April:

Pharming Group N.V. today announced the filing of its Annual Report for the year ended December 31, 2025.

Pharming Group N.V. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Joenja® (leniolisib) for the treatment of activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency, in adult and pediatric patients 12 years of age and older.

Pharming Group N.V. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Joenja® (leniolisib), an oral, selective phosphoinositide 3-kinase (PI3K) delta inhibitor, for the treatment of activated PI3K delta syndrome (APDS) in adult and pediatric patients aged 4 years and older.

Pharming Group N.V. presents its preliminary (unaudited) financial report for the three months and full year ended December 31, 2025.

Pharming Group N.V. confirms that it will report its preliminary (unaudited) financial results for the fourth quarter and full year 2025 and provide a business update on Thursday, March 12, 2026.